Back to Journals » International Journal of Women's Health » Volume 5

Letter to editor

Authors Reichmann J

Received 26 October 2012

Accepted for publication 31 October 2012

Published 22 January 2013 Volume 2013:5 Pages 35—36

DOI https://doi.org/10.2147/IJWH.S39590

Checked for plagiarism Yes



James P Reichmann

Sales & Marketing, American HomePatient, Brentwood, TN, USA,

I would like to congratulate the authors of the article entitled, "Optimal management of nausea and vomiting of pregnancy" for the comprehensive review of treatments for a frequent complication of pregnancy.1 Although this letter arrives well after publication I think it is important for researchers in the future to have clarification on one seemingly minor but important point. In order to avoid confusion it must be pointed out that in the metoclopramide section the statement "subcutaneous metoclopramide is effective in many women with NVP and HG" is supported by one observational trial on continuous subcutaneous metoclopramide.2 This distinction is very important because that study reported patients were receiving the drug for 26.7 days on average at a cost of $4432 per patient. Unfavorable cost comparisons have been previously published.3 The recommendation that more studied and less expensive alternatives are explored prior to subjecting the patient to this extreme measure seems prudent.4 Perhaps the use of the reference to continuous subcutaneous metoclopramide may have been accidental but the suggestion that "these findings are reassuring, especially for women who experience excessive sleepiness…" implies that women on Diclectin® who report being tired are advanced to continuous subcutaneous metoclopramide seems like a waste of health care resources and a little reckless.1

View original paper by Ebrahimi and colleagues.

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.